Showing 3771-3780 of 8598 results for "".
- Meta-Analysis IDs Promising Therapies for Hidradenitis Suppurativahttps://practicaldermatology.com/news/meta-analysis-ids-promising-therapies-for-hidradenitis-suppurativa/2475515/A new network meta-analysis comparing treatments for moderate to severe hidradenitis suppurativa (HS) shows several agents offering significantly improved efficacy over placebo. Researchers reviewed phase 2 and 3 randomized c
- Aesthetic Management Partners Launches New Non-Surgical Skin Revitalization Systemhttps://practicaldermatology.com/news/aesthetic-management-partners-launches-new-non-surgical-skin-revitalization-system/2475272/Aesthetic Management Partners announced the launch of PLADUOpro, a dual argon and nitrogen gas plasma system designed for advanced skin restoration, earlier this month.
- Analysis: No Added MACE Risk With Ustekinumab in Psoriasis and PsAhttps://practicaldermatology.com/news/analysis-no-added-mace-risk-with-ustekinumab-in-psoriasis-and-psa/2475231/New research suggests no difference in the risk of major adverse cardiovascular events (MACE) among patients with psoriasis (PsO) and psoriatic arthritis (PsA) initiating ustekinumab compared to adalimumab, etanercept, or secukinumab.
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- Midmark Announces First USAB Compliant Procedure Chairhttps://practicaldermatology.com/news/Midmark-Announces-First-USAB-Compliant-Procedure-Chair/2475173/Midmark Corp. announced the launch of the Midmark 631 procedure chair, which the company said is the first US Access Board (USAB) compliant procedure chair. In 2024, the U.S. Access Board issued a new standard establishing design criteria for examination and procedure chairs, as well
- Study: Strontium Cream Could Help Manage Pruritus in HShttps://practicaldermatology.com/news/Study-Strontium-Cream-Could-Help-Manage-Pruritus-HS/2475142/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to new research published in the Journal of Clinical and Aesthetic Dermatology. Statistical analysis of baseline and 1-week post-intervention surveys amon
- Study: Belly Fat More Predictive of Psoriasis Than Overall Body Fathttps://practicaldermatology.com/news/study-belly-fat-more-predictive-of-psoriasis-than-overall-body-fat/2475108/Central adiposity—particularly abdominal fat—is more strongly linked to psoriasis risk than overall body fat, according to a new analysis published in the Journal of Investigative Dermatology.
- Analysis: Methotrexate Does Not Enhance Adalimumab Outcomes in Psoriasishttps://practicaldermatology.com/news/methotrexate-does-not-enhance-adalimumab-outcomes-in-psoriasis/2475072/Concomitant methotrexate does not improve the effectiveness or persistence of adalimumab in plaque psoriasis, according to findings from a new study. Researchers investigating whether methotrexate enhances adalimumab’s durab
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi